Urology at Brigham and Women’s Hospital continues to play a leadership role in developing new therapies for prostate cancer, benign prostate disease, and bladder dysfunction. Members of our clinical staff are all on the faculty of Harvard Medical School and represent international leaders in each of these areas, as well as bladder cancer, testis cancer, renal cell carcinoma, men’s sexual dysfunction, and robotic surgery. Our services include urologic oncology, robotic and minimally invasive surgery, BWH Men's Sexual Health Clinic, and urodynamics.
Our research faculty represent international leaders in areas including molecular genetics, image-guided radiotherapy, tumor markers and surgical robotics. Other technologies in which BWH urologists are leaders include photoselective vaporization of prostate tissue (PVP laser) for benign prostate hyperplasia (BPH), bladder neurostimulation (Interstim® technology), and cryoablation of kidney tumors.
Our staff, under the direction of the Chief, Adam Kibel, MD, is the surgical oncology team for the Genitourinary Cancer Treatment Program at the Dana-Farber/Brigham and Women’s Cancer Center. This integrated cancer center in adult oncology brings together genitourinary, radiation, and medical oncologists with urological surgeons to treat patients as one medical team.
Send Feedback to:
Christopher Jones
This page was last modified on 1/11/2012